Oriel Therapeutics
Specialty pharmaceutical company developing and commercializing products to improve respiratory care
About Oriel Therapeutics
Oriel Therapeutics, established in 2001, operated as a specialty pharmaceutical firm with a strategic focus on the respiratory drug market. The company was co-founded by Dr. Paul J. Atkins, who brought extensive experience from his previous roles at GlaxoSmithKline, including the development of major respiratory products. His background in physical organic chemistry and deep knowledge of inhaled medicines were foundational to the company's direction.
The firm's primary business was the development of generic alternatives to brand-name medications for asthma and chronic obstructive pulmonary disease (COPD). Oriel's strategy centered on creating fully substitutable generic versions of key patented drugs, positioning itself to capitalize on the expiration of major patents in the substantial global market for asthma and COPD treatments. The company's operations were financed through venture capital, securing over $35 million in funding from investors including New Leaf Venture Partners, Thomas, McNerney & Partners, HealthCare Ventures, and CHL Medical Partners.
Oriel's core asset was its proprietary drug delivery platform. This included the innovative FreePath™ drug delivery technology and the Solis™ disposable dry powder inhaler (DPI). The technology was designed to overcome regulatory hurdles for generic inhaled medicines. A key patent covered the design of multi-dose dry powder packages that could be individually activated by a customized electrical input, causing them to vibrate for efficient aerosolization and drug dispersion. This system aimed to provide a more effective and user-friendly administration of inhaled therapies. The initial technology was licensed from the University of North Carolina at Chapel Hill.
A significant milestone in the company's history was its acquisition by Sandoz, the generics division of Novartis, in April 2010. Following the acquisition, Oriel was integrated as a separate development unit within Sandoz, allowing the larger firm to leverage Oriel's technology and product pipeline to enhance its position in the differentiated generics market. The terms of the acquisition were not publicly disclosed, but included potential milestone payments and sales royalties for Oriel's former owners.
Source: Dealroom company dataAt a glance
- Status
- Closed
- Open positions
- None listed
- Sector
- Spinout
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VC✓Equity / VC | Nov 2007 | $27M | $106M | New Leaf Venture Partners | — |
| SPINOUT✓Other financing | Jan 2001 | $0 | — | University of North Carolina at Chapel Hill | — |
Growth signals
Latest recorded traffic for Oriel Therapeutics is 0 monthly website visits, down 100% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Oriel Therapeutics in the Tarboro ecosystem
The Oriel Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
New Leaf Venture Partners
Other known investors1 additional known investor
University of North Carolina at Chapel Hill
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Oriel Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Oriel Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.






